Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Moscow Region, Russia.
Scientific and Educational Center of the Moscow State Regional University in Chernogolovka, Medical Biological Institute, Mytishchi, Moscow region, Russia.
Bull Exp Biol Med. 2023 May;175(1):23-26. doi: 10.1007/s10517-023-05803-4. Epub 2023 Jun 20.
We studied the possibility of inhibition of histone deacetylases (HDAC) in the nuclear extract of HeLa cells by N1-hydroxy-N4-(pyridin-4-yl)succinamide (compound 1). Compound 1 inhibits HDAC and showed low toxicity for A-172, HepG2, HeLa, MCF-7, and Vero cells. HeLa cells were most sensitive to the compound. Increasing the interval between administration of compound 1 and the chemotherapeutic agent to 8 h led to an increase in the cytotoxic effect of cisplatin (actinomycin D) on HeLa cells. The combination of compound 1 with cisplatin (actinomycin D) reduced the cytotoxic effect of these drugs for non-tumor Vero cells.
我们研究了 N1-羟基-N4-(吡啶-4-基)琥珀酰胺（化合物 1）对 HeLa 细胞核提取物中组蛋白去乙酰化酶（HDAC）的抑制作用。化合物 1 抑制 HDAC，对 A-172、HepG2、HeLa、MCF-7 和 Vero 细胞的毒性较低。HeLa 细胞对该化合物最为敏感。增加化合物 1 和化疗药物之间的间隔至 8 小时，导致顺铂（放线菌素 D）对 HeLa 细胞的细胞毒性作用增强。化合物 1 与顺铂（放线菌素 D）联合使用降低了这些药物对非肿瘤 Vero 细胞的细胞毒性作用。
